An interventional study of Physical activity and Physical activity and nutrition in Hematologic Cancer, sponsored by Instituto de Investigacion Sanitaria INCLIVA. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Instituto de Investigacion Sanitaria INCLIVA · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Hematologic Neoplasms with a site in Spain — 25 open to participants now, 36 under way, 5 of them phase 3. Hematologic Neoplasms · Spain.
Among the 77 studies in Hematologic Neoplasms with a site in Spain, this one is the 11th largest by planned enrollment of the 65 interventional ones that give a count, is one of 5 that started in 2025, is one of 5 with no phase, reaches primary completion later than 15 of the 35 other live ones, and was the 70th registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →25 of the 77 studies in Hematologic Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 18+
Merck Sharp & Dohme LLC · Sites in Spain, Colombia, Israel
Ages 18+
CSL Behring · Sites in Spain, United States, Belgium and 8 more countries
Ages 18+
Instituto de Investigación Biomédica de Salamanca · Sites in Spain
Ages 18+
Quetzal Therapeutics · Sites in Spain, United States, France and 2 more countries
Ages 18–71
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 28 · Phase 3 13 · Phase 4 2
First in 2001; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 338 is above the median of 46 across 1,047 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 135 across the 65 interventional studies, 701 across the 12 observational. Of the 36 that completed or were terminated, 17 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 77 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Instituto de Investigacion Sanitaria INCLIVA as lead sponsor.
Instituto de Investigacion Sanitaria INCLIVA has 1 study filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
9 of the studies in Hematologic Neoplasms with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07504458Phase 3Quetzal TherapeuticsPivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | 2027-03 |
| NCT06001788Kura Oncology, Inc.Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | 2026-12 |
| NCT06645886Kumquat Biosciences Inc.A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies | 2027-03 |
| NCT04068597CellCentric Ltd.Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | 2027-03-31 |
| NCT04634552Janssen Research & Development, LLCA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | 2027-06-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 77 studies in Hematologic Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if two non-pharmacological strategies can help reduce neurotoxicity caused by CAR-T cell therapy in adult patients with hematologic cancer, both sexes, aged 18 to 80 years. The strategies are:
The main questions it aims to answer are:
Researchers will compare two intervention groups with a control group (no intervention) to see which approach is most effective in reducing neurotoxicity and improving recovery.
Participants will be randomly assigned to one of three groups using stratified randomization to ensure balanced clinical and demographic characteristics:
Participants will be evaluated periodically by study professionals. Comprehensive records of symptoms, health measurements, and relevant lifestyle data will be maintained throughout the study.
A parallel-group, multicenter and randomized controlled clinical trial will be conducted from July 2025 to July 2027. The study will evaluate the effectiveness of two non-pharmacological interventions in reducing neurotoxicity associated with CAR-T cell therapy in adult patients with hematologic cancer.
A total of 100 patients will be enrolled and randomly assigned into three groups using stratified randomization performed by an individual external to the research team.
The intervention will begin at least one month prior to CAR-T cell infusion. Participants will be followed weekly before, during, and for four weeks after therapy. Interventions and evaluations will be carried out in the same hospital where the patient receives treatment, and always by the same multidisciplinary team (hematologists, nurses, nutritionists, physiotherapists).
Primary and secondary outcomes will be assessed at baseline (prior to intervention), during treatment, and post-treatment follow-up. Written informed consent will be obtained from all participants before enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients assigned to intervention group A will follow a supervised programme of physical activity and exercise at home and during their hospital stay. These recommendations are designed and supervised by a physiotherapist. The programme will include three weekly aerobic exercise sessions and two resistance exercise sessions, as recommended in the literature. Each session will last approximately 35 minutes and will include a warm-up, training and cool-down. All patients will follow the same exercise programme, which will be adapted to a basic, intermediate and advanced level to adapt to the patients' physical condition. The loads, intensity and number of sets will be adapted for each level. The programme is scheduled to commence one month prior to the initiation of CAR-T therapy. It is recommended that patients adhere to the professional's guidelines for a period of at least one month following treatment.
Other: Physical activity
The intervention combines a structured physical activity programme with individualised nutritional recommendations based on the Mediterranean diet. These recommendations are designed and supervised by a nutritionist and a physiotherapist. The macronutrient distribution followed standard guidelines (50-55% carbohydrates, 30-35% fats, 10-15% proteins), emphasising vegetables, fruits, legumes, cereals, dairy, lean meats, fish, nuts, and olive oil. Each food group contributes bioactive compounds with anti-inflammatory and antioxidant properties, including lycopene, quercetin, anthocyanins, genistein, ferulic acid, SCFAs, omega-3 fatty acids and polyphenols. These have been shown to mitigate oxidative stress, inflammation and toxicological effects, thereby supporting cardio. The programme is scheduled to commence one month prior to the initiation of CAR-T therapy. It is recommended that patients adhere to the professional's guidelines for a period of at least one month following treatment.
Other: Physical activity · Other: Physical activity and nutrition
The control group will serve to establish a baseline for identifying clinical, demographic, and response patterns of the studied variables. All procedures and interventions will be conducted in accordance with the center's standard clinical practice.
Patients assigned to intervention group A will follow a supervised programme of physical activity and exercise at home and during hospitalisation. All patients will follow the same exercise programme, which will be adapted to a basic, intermediate and advanced level to suit the patients' physical condition. The loads, intensity and number of sets will be adapted to each level. Aerobic exercise will consist of walking and/or cycling at an intensity of between two and five on the Borg perceived exertion (RPE) scale. Resistance exercise will consist of one session focusing on the trunk and upper limbs, and another on the lower limbs. Both sessions will include seven exercises, performed at an intensity of between three and four on the Borg RPE scale.
The intervention integrates a structured physical activity programme with individualized nutritional recommendations based on the Mediterranean diet. Macronutrient distribution was 50-55% carbohydrates, 30-35% fats, and 10-15% proteins. The protocol emphasized the intake of vegetables (≥2 servings/day, 200 g each), fruits (1-2 servings/day, 150 g each), legumes (≥3 servings/week, 150 g cooked), whole grains (1-2 servings/meal, 40-60 g), and low-fat dairy products (1-2 servings/day; 200 ml milk or 125 g yoghurt). Lean meats were prescribed at 3-4 servings/week (100-125 g each), fish and seafood at 4 servings/week (150 g each), nuts at 3-7 servings/week (30 g each), and olive oil as the principal fat source (≤4 tbsp/day). Micronutrients and bioactive compounds from these foods, including antioxidants, polyphenols, and essential fatty acids, were recognized as pivotal for modulating protective mechanisms and mitigating toxicological effects.
Incidence and severity of neurotoxicity as assessed by American Society for Transplantation and Cellular Therapy (ASCT) Immune Effector Cell-Associated Encephalopathy (ICE) consensus grading system
Patients will undergo a standardised neurological evaluation. The American Society for Transplantation and Cellular Therapy (ASCT) classifies immune effector cell-associated encephalopathy (ICE), which grades the associated neurotoxicity from 1 to 4. It consists of five domains: ICE score, decreased level of consciousness, convulsions, motor findings and elevated intracranial pressure or cerebral oedema. The ICE score evaluates five cognitive domains (orientation, object naming, following instructions, writing and attention) with a maximum score of 10 points.
Time frame: At baseline and from the infusion of treatment until 15 days after CAR-T therapy.
Functional independence as assessed by the Lawton and Brody Instrumental Activities of Daily Living (IADL) scale
Functional capacity will be assessed using the Lawton and Brody Instrumental Activities of Daily Living (IADL) scale . This instrument evaluates the patient's ability to perform eight instrumental activities essential for independent living (e.g., using the telephone, shopping, preparing meals, housekeeping, laundry, transportation, medication management, and financial management). Each item is scored as 0 (dependent) or 1 (independent), yielding a total score ranging from 0 (total dependence) to 8 (complete independence). Higher scores indicate greater independence and better functional status.
Time frame: At baseline and from the infusion of treatment until 15 days after CAR-T therapy.
Physical activity level as assessed by the International Physical Activity Questionnaire (IPAQ)
Physical activity will be quantified using the International Physical Activity Questionnaire (IPAQ). The instrument comprises seven items and provides information on the time spent walking, performing moderate-intensity activities, vigorous-intensity activities, and sedentary behaviour during the last seven days. The results are expressed in metabolic equivalent task minutes per week (MET-min/week) and categorised into three levels of physical activity: * Low: no or insufficient activity. * Moderate: ≥3 days of vigorous activity (20 minutes/day), ≥5 days of moderate activity or walking (30 minutes/day), or a combination reaching ≥600 MET-min/week. * High: vigorous activity on ≥3 days achieving ≥1,500 MET-min/week, or 7 days of any combination reaching ≥3,000 MET-min/week. This classification allows the identification of patients at risk of inactivity and facilitates monitoring of changes across the intervention.
Time frame: At baseline and from the infusion of treatment until 15 days after CAR-T therapy.
Nutritional status as assessed by the Patient-Generated Subjective Global Assessment (PG-SGA)
Nutritional status will be evaluated using the Patient-Generated Subjective Global Assessment (PG-SGA), a tool that has been validated for the purpose of nutritional screening in oncohematology. The PG-SGA combines patient-reported data and clinician assessment, including weight changes, dietary intake, nutrition impact symptoms, functional capacity, and physical examination findings. Patients are categorised into three groups: well-nourished, moderately malnourished/at risk of malnutrition, or severely malnourished. The instrument facilitates the identification of patients requiring nutritional interventions, thereby providing a comprehensive overview of nutritional risk within the study population.
Time frame: At baseline and from the infusion of treatment until 15 days after CAR-T therapy.
Quality of life as assessed by the Short Form 12 (SF-12)
Quality of life will be assessed using the Short Form 12 (SF-12) health survey. The SF-12 evaluates eight health domains, which are aggregated into two summary scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Each domain is scored according to the SF-12 scoring algorithm, resulting in standardized scores ranging from 0 to 100, with higher scores indicating better health-related quality of life.
Time frame: At baseline and from the infusion of treatment until 15 days after CAR-T therapy.
Adherence to interventions
The researcher collected attendance records, food records and self-reported activity levels as part of the follow-up of the subjects.
Time frame: At baseline and from the infusion of treatment until 15 days after CAR-T therapy.
Length of initial hospital stay
Duration of the initial hospitalisation following CAR-T infusion will be documented from the day of admission until discharge (days).
Time frame: From the infusion of treatment until 15 days after CAR-T therapy.
Number of hospital readmissions
Hospital readmissions related to the intervention will be documented, including cause and date of readmission (number of readmissions per participant).
Time frame: From the infusion of treatment until 15 days after CAR-T therapy.
Plan to share: No — The dissemination of individual participant data will not occur directly. All information related to the study, including the protocol, detailed study design, primary and secondary outcomes, and summary results, will be shared through peer-reviewed scientific publications, conference abstracts, and academic presentations. This approach ensures full transparency of the study's methodology, analyses, and findings, while strictly protecting participant privacy, maintaining confidentiality, and complying with all relevant ethical, legal, and regulatory standards.
Started Sep 2025 (actual). Primary completion is estimated for Jul 2027, 22 months after the start.
Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 22 months is below that.
Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.